Global Scleroderma Therapeutics Market Research Report 2023

Publication ID:

PB511243988

Publication Date:

November 13, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
The global Scleroderma Therapeutics market is projected to reach US$ 1827.1 million in 2029, increasing from US$ 1402.3 million in 2022, with the CAGR of 3.4% during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Scleroderma Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
Segment by Type
Immunosuppressors
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Segment by Application
Systemic
Localized
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Scleroderma Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunosuppressors
1.2.3 Phosphodiesterase 5 Inhibitors - PHA
1.2.4 Endothelin Receptor Antagonists
1.2.5 Prostacyclin Analogues
1.2.6 Calcium Channel Blockers
1.2.7 Analgesics
1.2.8 Others
1.3 Market by Application
1.3.1 Global Scleroderma Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Systemic
1.3.3 Localized
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Scleroderma Therapeutics Market Perspective (2018-2029)
2.2 Scleroderma Therapeutics Growth Trends by Region
2.2.1 Global Scleroderma Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Scleroderma Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Scleroderma Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Scleroderma Therapeutics Market Dynamics
2.3.1 Scleroderma Therapeutics Industry Trends
2.3.2 Scleroderma Therapeutics Market Drivers
2.3.3 Scleroderma Therapeutics Market Challenges
2.3.4 Scleroderma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Scleroderma Therapeutics Players by Revenue
3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue
3.4 Global Scleroderma Therapeutics Market Concentration Ratio
3.4.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2022
3.5 Scleroderma Therapeutics Key Players Head office and Area Served
3.6 Key Players Scleroderma Therapeutics Product Solution and Service
3.7 Date of Enter into Scleroderma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Scleroderma Therapeutics Breakdown Data by Type
4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2024-2029)
5 Scleroderma Therapeutics Breakdown Data by Application
5.1 Global Scleroderma Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Scleroderma Therapeutics Market Size (2018-2029)
6.2 North America Scleroderma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Scleroderma Therapeutics Market Size by Country (2018-2023)
6.4 North America Scleroderma Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Scleroderma Therapeutics Market Size (2018-2029)
7.2 Europe Scleroderma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Scleroderma Therapeutics Market Size by Country (2018-2023)
7.4 Europe Scleroderma Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Scleroderma Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Scleroderma Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Scleroderma Therapeutics Market Size (2018-2029)
9.2 Latin America Scleroderma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Scleroderma Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Scleroderma Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Scleroderma Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Scleroderma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 F. Hoffmann-La Roche AG Company Detail
11.1.2 F. Hoffmann-La Roche AG Business Overview
11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2018-2023)
11.1.5 F. Hoffmann-La Roche AG Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2018-2023)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Detail
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2018-2023)
11.3.5 Celgene Corporation Recent Development
11.4 Argentis Pharmaceuticals, LLC
11.4.1 Argentis Pharmaceuticals, LLC Company Detail
11.4.2 Argentis Pharmaceuticals, LLC Business Overview
11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
11.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2018-2023)
11.4.5 Argentis Pharmaceuticals, LLC Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Scleroderma Therapeutics Introduction
11.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2018-2023)
11.5.5 Bayer AG Recent Development
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Company Detail
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
11.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2018-2023)
11.6.5 Boehringer Ingelheim International GmbH Recent Development
11.7 Akashi Therapeutics
11.7.1 Akashi Therapeutics Company Detail
11.7.2 Akashi Therapeutics Business Overview
11.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
11.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2018-2023)
11.7.5 Akashi Therapeutics Recent Development
11.8 Prometic Life Sciences, Inc.
11.8.1 Prometic Life Sciences, Inc. Company Detail
11.8.2 Prometic Life Sciences, Inc. Business Overview
11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
11.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.8.5 Prometic Life Sciences, Inc. Recent Development
11.9 Emerald Health Pharmaceuticals
11.9.1 Emerald Health Pharmaceuticals Company Detail
11.9.2 Emerald Health Pharmaceuticals Business Overview
11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
11.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2018-2023)
11.9.5 Emerald Health Pharmaceuticals Recent Development
11.10 Kadmon Holdings, Inc.
11.10.1 Kadmon Holdings, Inc. Company Detail
11.10.2 Kadmon Holdings, Inc. Business Overview
11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
11.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.10.5 Kadmon Holdings, Inc. Recent Development
11.11 Seattle Genetics, Inc.
11.11.1 Seattle Genetics, Inc. Company Detail
11.11.2 Seattle Genetics, Inc. Business Overview
11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
11.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.11.5 Seattle Genetics, Inc. Recent Development
11.12 Cytori Therapeutics, Inc.
11.12.1 Cytori Therapeutics, Inc. Company Detail
11.12.2 Cytori Therapeutics, Inc. Business Overview
11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
11.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.12.5 Cytori Therapeutics, Inc. Recent Development
11.13 Fibrocell Science, Inc.
11.13.1 Fibrocell Science, Inc. Company Detail
11.13.2 Fibrocell Science, Inc. Business Overview
11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
11.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.13.5 Fibrocell Science, Inc. Recent Development
11.14 Chemomab
11.14.1 Chemomab Company Detail
11.14.2 Chemomab Business Overview
11.14.3 Chemomab Scleroderma Therapeutics Introduction
11.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2018-2023)
11.14.5 Chemomab Recent Development
11.15 Corbus Pharmaceuticals Holdings, Inc.
11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Detail
11.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview
11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
11.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2018-2023)
11.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development
11.16 Genkyotex
11.16.1 Genkyotex Company Detail
11.16.2 Genkyotex Business Overview
11.16.3 Genkyotex Scleroderma Therapeutics Introduction
11.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2018-2023)
11.16.5 Genkyotex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂